QualityStocks

[QualityStocks]

QualityStocksNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Subsidiary Receives Import License from Australia

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF), through wholly-owned subsidiary ABcann Australia Pty Ltd., this morning announced that it has received an import license from the Federal Office of Drug Control in Australia. Following receipt of necessary approvals, including approval from the TSX Venture Exchange, ABcann intends to supply medicinal cannabis to the Australian market via the Australian Department of Health’s Therapeutic Goods Administration (“TGA”) Special Access Scheme. “This import license is a key milestone towards generating revenue through ABcann’s network of physicians, pharmacists and patients, and advancing the use of medical cannabis,” Barry Fishman, chief executive officer of ABcann, stated in the news release. “We view Australia as an important emerging market for medical cannabis and I look forward to meeting with our strategic partners and stakeholders in Australia later this month to further discuss opportunities there.”

To view the full press release, visit http://ibn.fm/TRDHZ

About ABcann Global Corp.

ABcann holds production and sales licenses from Health Canada. Its flagship facility in Napanee, Ontario contains proprietary plant-growing technology, centered on its specially designed, environmentally-controlled growing chambers. This approach results in the production of pharmaceutical-grade cannabis products. The company is expanding its cultivation capacity and pursuing partnership and product development opportunities domestically, as well as in select international markets, such as Germany, Australia and Israel. For more information, visit www.ABcannGlobal.com